Category: Balstilimab

  • Agenus Reports the Withdrawal of BLA for Balstilimab to Treat Cervical Cancer

    Shots: The company has reported the voluntary withdraw of balstilimab’s BLA in patients with cervical cancer, following the US FDA’s recommendation & the decision follows the full approval of pembrolizumab The company will discontinue its ongoing BRAVA trial evaluating Balstilimab & plans to launch expanded access programs to provide patient access to balstilimab in multiple […]